Maynard Um
-
-
-
-
-
-
-
FDA approves first gene therapy for Sanfilippo syndrome type A
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright
-
-
-
-
-
-
-
Evercore ISI Downgrades Ultragenyx Pharma (RARE) to In Line
-
-
-
-
-
-
-
Citi raises Ultragenyx price target to $58 after FDA approval
-
-
-
-
-
-
-
Leerink Partners on Ultragenyx Pharma (RARE): FDA BLA acceptance positions co for two approvals, $150M oppty
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $79 at Canaccord Genuity
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $58 at BofA Securities
-
466,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


